Joseph Bennington-Castro is a Hawaii-based contributing writer for Live Science and . He holds a master's degree in science journalism from New York University, and a bachelor's degree in physics from the University of Hawaii. His work covers all areas of science, from the quirky mating behaviors of different animals, to the drug and alcohol habits of ancient cultures, to new advances in solar cell technology. On a more personal note, Joseph has had a near-obsession with video games for as long as he can remember, and is probably playing a game at this very moment.
Last night I heard a statistic my oncologist told a fellow patient and now friend of mine regarding our estimated life expectancy post this type of breast cancer (while explaining to her why she should now take that darn chemo pill I narrowly escaped). I won't share the number here because it's messing with my mind, but know it's not nearly big enough and involves me never seeing James be anywhere close to my current age. It's the first thing I thought of this morning and I can't shake it. I guess it's a big wake up call for me to right the ship. Focus on what I want my life to be, what choices I need to make in my daily life and how to stay motivated to be the healthiest version of myself I can be. I also need to remember that it's an average, not the rule. Of course, I've never been one for rules much anyway.
A multi-center, single-arm, open-label study was conducted in 28 girls with McCune-Albright Syndrome and progressive precocious puberty aged 2 to < 10 years. All patients received a 1 mg daily dose of ARIMIDEX. The trial duration was 12 months. Patients were enrolled on the basis of a diagnosis of typical (27/28) or atypical (1/27) McCune-Albright Syndrome, precocious puberty, history of vaginal bleeding, and/or advanced bone age. Patients' baseline characteristics included the following: a mean chronological age of ± years, a mean bone age of ± years, a mean growth rate of ± cm/year and a mean Tanner stage for breast of ± . Compared to pre-treatment data there were no on-treatment statistically significant reductions in the frequency of vaginal bleeding days, or in the rate of increase of bone age (defined as a ratio between the change in bone age over the change of chronological age). There were no clinically significant changes in Tanner staging , mean ovarian volume, mean uterine volume and mean predicted adult height. A small but statistically significant reduction of growth rate from ± cm/year to ± cm/year was observed but the absence of a control group precludes attribution of this effect to treatment or to other confounding factors such as variations in endogenous estrogen levels commonly seen in McCune-Albright Syndrome patients.